596 related articles for article (PubMed ID: 33637088)
1. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis.
Li F; Ye J; Shao C; Zhong B
Lipids Health Dis; 2021 Feb; 20(1):22. PubMed ID: 33637088
[TBL] [Abstract][Full Text] [Related]
2. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.
Boursier J; Mueller O; Barret M; Machado M; Fizanne L; Araujo-Perez F; Guy CD; Seed PC; Rawls JF; David LA; Hunault G; Oberti F; Calès P; Diehl AM
Hepatology; 2016 Mar; 63(3):764-75. PubMed ID: 26600078
[TBL] [Abstract][Full Text] [Related]
3. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
4. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease.
Shen F; Zheng RD; Sun XQ; Ding WJ; Wang XY; Fan JG
Hepatobiliary Pancreat Dis Int; 2017 Aug; 16(4):375-381. PubMed ID: 28823367
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach.
Del Chierico F; Nobili V; Vernocchi P; Russo A; De Stefanis C; Gnani D; Furlanello C; Zandonà A; Paci P; Capuani G; Dallapiccola B; Miccheli A; Alisi A; Putignani L
Hepatology; 2017 Feb; 65(2):451-464. PubMed ID: 27028797
[TBL] [Abstract][Full Text] [Related]
6. Gut Microbial Dysbiosis in the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies.
Wang L; Alammar N; Singh R; Nanavati J; Song Y; Chaudhary R; Mullin GE
J Acad Nutr Diet; 2020 Apr; 120(4):565-586. PubMed ID: 31473156
[TBL] [Abstract][Full Text] [Related]
7. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan.
Tsai MC; Liu YY; Lin CC; Wang CC; Wu YJ; Yong CC; Chen KD; Chuah SK; Yao CC; Huang PY; Chen CH; Hu TH; Chen CL
Nutrients; 2020 Mar; 12(3):. PubMed ID: 32204538
[TBL] [Abstract][Full Text] [Related]
8. Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease.
Takahashi K; Nishida A; Fujimoto T; Fujii M; Shioya M; Imaeda H; Inatomi O; Bamba S; Sugimoto M; Andoh A
Digestion; 2016; 93(1):59-65. PubMed ID: 26789999
[TBL] [Abstract][Full Text] [Related]
9. Changes of intestinal bacterial microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease.
Zhang Y; Xu J; Wang X; Ren X; Liu Y
BMC Genomics; 2019 Nov; 20(1):862. PubMed ID: 31726978
[TBL] [Abstract][Full Text] [Related]
10. An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesity.
Nistal E; Sáenz de Miera LE; Ballesteros Pomar M; Sánchez-Campos S; García-Mediavilla MV; Álvarez-Cuenllas B; Linares P; Olcoz JL; Arias-Loste MT; García-Lobo JM; Crespo J; González-Gallego J; Jorquera Plaza F
Rev Esp Enferm Dig; 2019 Apr; 111(4):275-282. PubMed ID: 30810328
[TBL] [Abstract][Full Text] [Related]
11. Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
Schwimmer JB; Johnson JS; Angeles JE; Behling C; Belt PH; Borecki I; Bross C; Durelle J; Goyal NP; Hamilton G; Holtz ML; Lavine JE; Mitreva M; Newton KP; Pan A; Simpson PM; Sirlin CB; Sodergren E; Tyagi R; Yates KP; Weinstock GM; Salzman NH
Gastroenterology; 2019 Oct; 157(4):1109-1122. PubMed ID: 31255652
[TBL] [Abstract][Full Text] [Related]
12. Gut Microbiota, Glucose, Lipid, and Water-Electrolyte Metabolism in Children With Nonalcoholic Fatty Liver Disease.
Pan X; Kaminga AC; Liu A; Wen SW; Luo M; Luo J
Front Cell Infect Microbiol; 2021; 11():683743. PubMed ID: 34778099
[TBL] [Abstract][Full Text] [Related]
13. The Relationship Between Pediatric Gut Microbiota and SARS-CoV-2 Infection.
Romani L; Del Chierico F; Macari G; Pane S; Ristori MV; Guarrasi V; Gardini S; Pascucci GR; Cotugno N; Perno CF; Rossi P; Villani A; Bernardi S; Campana A; Palma P; Putignani L;
Front Cell Infect Microbiol; 2022; 12():908492. PubMed ID: 35873161
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance.
Da Silva HE; Teterina A; Comelli EM; Taibi A; Arendt BM; Fischer SE; Lou W; Allard JP
Sci Rep; 2018 Jan; 8(1):1466. PubMed ID: 29362454
[TBL] [Abstract][Full Text] [Related]
15. Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time?
Demir M; Lang S; Martin A; Farowski F; Wisplinghoff H; Vehreschild MJGT; Krawczyk M; Nowag A; Scholz CJ; Kretzschmar A; Roderburg C; Lammert F; Goeser T; Kasper P; Steffen HM
J Gastroenterol Hepatol; 2020 Nov; 35(11):1969-1977. PubMed ID: 32267559
[TBL] [Abstract][Full Text] [Related]
16. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease.
Wieland A; Frank DN; Harnke B; Bambha K
Aliment Pharmacol Ther; 2015 Nov; 42(9):1051-63. PubMed ID: 26304302
[TBL] [Abstract][Full Text] [Related]
17. Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease: a large BMI- and sex-matched population study.
Iino C; Endo T; Mikami K; Hasegawa T; Kimura M; Sawada N; Nakaji S; Fukuda S
Hepatol Int; 2019 Nov; 13(6):748-756. PubMed ID: 31515740
[TBL] [Abstract][Full Text] [Related]
18. Alterations in the gut microbiota of patients with acquired immune deficiency syndrome.
Zhou Y; Ou Z; Tang X; Zhou Y; Xu H; Wang X; Li K; He J; Du Y; Wang H; Chen Y; Nie Y
J Cell Mol Med; 2018 Apr; 22(4):2263-2271. PubMed ID: 29411528
[TBL] [Abstract][Full Text] [Related]
19. Fecal Microbiota in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: A Systematic Review.
Mohammadi Z; Poustchi H; Motamed-Gorji N; Eghtesad S; Hekmatdoost A; Saniee P; Merat S
Arch Iran Med; 2020 Jan; 23(1):44-52. PubMed ID: 31910634
[TBL] [Abstract][Full Text] [Related]
20. Microbial Intervention as a Novel Target in Treatment of Non-Alcoholic Fatty Liver Disease Progression.
Zhou Y; Zheng T; Chen H; Li Y; Huang H; Chen W; Du Y; He J; Li Y; Cao J; Nie Y; Zhou Y
Cell Physiol Biochem; 2018; 51(5):2123-2135. PubMed ID: 30522122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
